{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:43:18Z","timestamp":1791830598664,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009358","name":"Duchenne UK","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009358","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s41669-023-00450-x","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T11:32:44Z","timestamp":1701257564000},"page":"79-89","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Developing a Natural History Model for Duchenne Muscular Dystrophy"],"prefix":"10.1007","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1846-2150","authenticated-orcid":false,"given":"Jonathan","family":"Broomfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Crowther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Godfrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Guglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hastie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Larkindale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mumby-Croft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Reuben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Woodcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. R.","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Project HERCULES, the Cooperative International Neuromuscular Research Group investigators, Duchenne Regulatory Science Consortium members","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"issue":"1","key":"450_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","volume":"15","author":"S Crisafulli","year":"2020","unstructured":"Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifiro G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15(1):141.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"450_CR2","first-page":"477","volume":"89","author":"PP San Mart\u00edn","year":"2018","unstructured":"San Mart\u00edn PP, Solis F, Cavada CG. Survival of patients with Duchenne muscular dystrophy. Rev Chil Pediatr. 2018;89(4):477.","journal-title":"Rev Chil Pediatr"},{"issue":"1","key":"450_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3233\/JND-140005","volume":"1","author":"JC van den Bergen","year":"2014","unstructured":"van den Bergen JC, Ginjaar HB, van Essen AJ, Pangalila R, de Groot IJ, Wijkstra PJ, et al. Forty-five years of duchenne muscular dystrophy in The Netherlands. J Neuromuscul Dis. 2014;1(1):99\u2013109.","journal-title":"J Neuromuscul Dis."},{"issue":"1","key":"450_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2018-000783","volume":"5","author":"M Wang","year":"2018","unstructured":"Wang M, Birnkrant DJ, Super DM, Jacobs IB, Bahler RC. Progressive left ventricular dysfunction and long-term outcomes in patients with Duchenne muscular dystrophy receiving cardiopulmonary therapies. Open Heart. 2018;5(1): e000783.","journal-title":"Open Heart."},{"issue":"1","key":"450_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7(1):13.","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"450_CR6","doi-asserted-by":"publisher","first-page":"18168","DOI":"10.3390\/molecules201018168","volume":"20","author":"MS Falzarano","year":"2015","unstructured":"Falzarano MS, Scotton C, Passarelli C, Ferlini A. Duchenne muscular dystrophy: from diagnosis to therapy. Molecules. 2015;20(10):18168\u201384.","journal-title":"Molecules"},{"issue":"5","key":"450_CR7","first-page":"CD003725","volume":"2016","author":"E Matthews","year":"2016","unstructured":"Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2016;2016(5):CD003725.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"450_CR8","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(22)00125-9","volume":"21","author":"T Markati","year":"2022","unstructured":"Markati T, Oskoui M, Farrar MA, Duong T, Goemans N, Servais L. Emerging therapies for Duchenne muscular dystrophy. Lancet Neurol. 2022;21(9):814\u201329.","journal-title":"Lancet Neurol"},{"key":"450_CR9","unstructured":"Rare Diseases: Natural History Studies for Drug Development\u2014FDA Draft Guidance for Industry (2019). Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/rare-diseases-natural-history-studies-drug-development. Accessed 11 May 2023"},{"key":"450_CR10","unstructured":"Best Practices for Development and Application of Disease Progression Models\u2014FDA Workshop (2021). Available at: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/best-practices-development-and-application-disease-progression-models-11192021. Accessed 11 May 2023."},{"issue":"4","key":"450_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/cpt.423","volume":"100","author":"NP Jewell","year":"2016","unstructured":"Jewell NP. Natural history of diseases: statistical designs and issues. Clin Pharmacol Ther. 2016;100(4):353\u201361.","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 2","key":"450_CR12","first-page":"S38","volume":"62","author":"J Liu","year":"2022","unstructured":"Liu J, Barrett JS, Leonardi ET, Lee L, Roychoudhury S, Chen Y, et al. Natural history and real-world data in rare diseases: applications, limitations, and future perspectives. J Clin Pharmacol. 2022;62(Suppl 2):S38\u201355.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"450_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77\u201393.","journal-title":"Lancet Neurol"},{"issue":"1","key":"450_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12891-019-2661-6","volume":"20","author":"YA Choi","year":"2019","unstructured":"Choi YA, Shin HI, Shin HI. Scoliosis in Duchenne muscular dystrophy children is fully reducible in the initial stage, and becomes structural over time. BMC Musculoskelet Disord. 2019;20(1):277.","journal-title":"BMC Musculoskelet Disord"},{"issue":"2","key":"450_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamacardio.2016.4910","volume":"2","author":"EM McNally","year":"2017","unstructured":"McNally EM. Cardiomyopathy in muscular dystrophy: when to treat? JAMA Cardiol. 2017;2(2):199.","journal-title":"JAMA Cardiol."},{"issue":"6","key":"450_CR16","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/jrsm.1434","volume":"11","author":"K Papadimitropoulou","year":"2020","unstructured":"Papadimitropoulou K, Stijnen T, Riley RD, Dekkers OM, le Cessie S. Meta-analysis of continuous outcomes: using pseudo IPD created from aggregate data to adjust for baseline imbalance and assess treatment-by-baseline modification. Res Synth Methods. 2020;11(6):780\u201394.","journal-title":"Res Synth Methods"},{"issue":"23","key":"450_CR17","doi-asserted-by":"publisher","first-page":"e2304","DOI":"10.1212\/WNL.0000000000012910","volume":"97","author":"J Broomfield","year":"2021","unstructured":"Broomfield J, Hill M, Guglieri M, Crowther M, Abrams K. Life expectancy in duchenne muscular dystrophy: reproduced individual patient data meta-analysis. Neurology. 2021;97(23):e2304\u201314.","journal-title":"Neurology"},{"issue":"12","key":"450_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"1","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;1(12):9.","journal-title":"BMC Med Res Methodol"},{"issue":"10","key":"450_CR19","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/S0960-8966(02)00140-2","volume":"12","author":"M Eagle","year":"2002","unstructured":"Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord. 2002;12(10):926\u20139.","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"450_CR20","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10654-020-00613-8","volume":"35","author":"E Landfeldt","year":"2020","unstructured":"Landfeldt E, Thompson R, Sejersen T, McMillan HJ, Kirschner J, Lochm\u00fcller H. Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. Eur J Epidemiol. 2020;35(7):643\u201353.","journal-title":"Eur J Epidemiol"},{"issue":"5","key":"450_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1053\/ejpn.2000.0309","volume":"4","author":"K Mohamed","year":"2000","unstructured":"Mohamed K, Appleton R, Nicolaides P. Delayed diagnosis of Duchenne muscular dystrophy. Eur J Paediatr Neurol. 2000;4(5):219\u201323.","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"450_CR22","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jpeds.2009.02.007","volume":"155","author":"E Ciafaloni","year":"2009","unstructured":"Ciafaloni E, Fox DJ, Pandya S, Westfield CP, Puzhankara S, Romitti PA, et al. Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). J Pediatr. 2009;155(3):380\u20135.","journal-title":"J Pediatr"},{"issue":"5","key":"450_CR23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10928-019-09642-7","volume":"46","author":"DJ Conrado","year":"2019","unstructured":"Conrado DJ, Larkindale J, Berg A, Hill M, Burton J, Abrams KR, et al. Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy. J Pharmacokinet Pharmacodyn. 2019;46(5):441\u201355.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"450_CR24","first-page":"149","volume":"87","author":"V Ricotti","year":"2016","unstructured":"Ricotti V, Ridout DA, Pane M, Main M, Mayhew A, Mercuri E, et al. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. J Neurol Neurosurg Psychiatry. 2016;87(2):149\u201355.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"450_CR25","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/humu.23561","volume":"39","author":"RT Wang","year":"2018","unstructured":"Wang RT, Barthelemy F, Martin AS, Douine ED, Eskin A, Lucas A, et al. DMD genotype correlations from the Duchenne Registry: endogenous exon skipping is a factor in prolonged ambulation for individuals with a defined mutation subtype. Hum Mutat. 2018;39(9):1193\u2013202.","journal-title":"Hum Mutat"},{"issue":"4","key":"450_CR26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1212\/WNL.0000000000002891","volume":"87","author":"L Bello","year":"2016","unstructured":"Bello L, Morgenroth LP, Gordish-Dressman H, Hoffman EP, McDonald CM, Cirak S, et al. DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study. Neurology. 2016;87(4):401\u20139.","journal-title":"Neurology"},{"key":"450_CR27","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1007\/s12325-022-02117-1","volume":"39","author":"J Iff","year":"2022","unstructured":"Iff J, Zhong Y, Gupta D, Paul X, Tuttle E, Henricson E, et al. Disease progression stages and burden in patients with Duchenne muscular dystrophy using administrative claims supplemented by electronic medical records. Adv Ther. 2022;39:2906\u201319.","journal-title":"Adv Ther"},{"issue":"2","key":"450_CR28","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40273-016-0461-5","volume":"35","author":"E Landfeldt","year":"2017","unstructured":"Landfeldt E, Alfredsson L, Straub V, Lochmuller H, Bushby K, Lindgren P. Economic evaluation in Duchenne muscular dystrophy: model frameworks for cost-effectiveness analysis. Pharmacoeconomics. 2017;35(2):249\u201358.","journal-title":"Pharmacoeconomics"},{"issue":"15","key":"450_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12883-015-0408-z","volume":"26","author":"L Merlini","year":"2015","unstructured":"Merlini L, Sabatelli P. Improving clinical trial design for Duchenne muscular dystrophy. BMC Neurol. 2015;26(15):153.","journal-title":"BMC Neurol"},{"issue":"10119","key":"450_CR30","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","volume":"391","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391(10119):451\u201361.","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1007\/s41669-024-00506-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000}}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-023-00450-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-023-00450-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-023-00450-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T02:26:13Z","timestamp":1720059973000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-023-00450-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["450"],"URL":"https:\/\/doi.org\/10.1007\/s41669-023-00450-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2405860\/v1","asserted-by":"object"}]},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,29]]},"assertion":[{"value":"18 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s41669-024-00506-6","URL":"https:\/\/doi.org\/10.1007\/s41669-024-00506-6","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Duchenne UK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Micki Hill has worked for GSK since April 2022. Keith Abrams is a partner and director of Visible Analytics Limited, a health technology assessment consultancy company; a National Institute for Health and Care Research (NIHR) Senior Investigator Emeritus (NF-SI-0512-10159); and a member of the National Institute for Health and Care Excellence (NICE) Diagnostics Advisory Committee. Jane Larkindale has worked for PepGen Inc. since April 2022. There are no other conflicts of interest for authors contributing to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"D-RSC data access applications can be made via\n                      \n                      . Access to the mortality data set and the simulated individual patient data obtained from the elicitation exercise in this study are available on request from jb781@leicester.ac.uk.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"All studies within the D-RSC dataset are fully de-identified and compliant to the terms and conditions specified by the data owners, with more information at\n                      \n                      . Further analysis of the D-RSC dataset and methods of the elicitation exercise were reviewed and approved by the University of Leicester ethics committee (ref number: 32556-jb781-Ls:healthsciences).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants were provided with an information sheet and required to provide informed consent before completing the elicitation exercise.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Participants in the online elicitation exercise were presented with a comprehensive information sheet, and by taking part, gave consent for the results of the exercise to be published anonymously.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A multi-state model was fitted in R using the <i>msm<\/i> package, allowing for piecewise-constant transition intensities, with details of the analysis described in the main body of text.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"EC and FC conceived the study; EC acquired the funding; KRA and MH designed the study; JG provided project administration; JL supervised the conduct of the study and data collection; JL and MH managed the data, including quality control; KRA, MH, MG, JB and MJC provided statistical advice on study design and analysed the data; KRA, JB, JM-C and FW drafted the manuscript; FC, JH and MG conducted the writing review; and JB is responsible for the whole paper.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}